Zogenix files for $90M IPO

After gathering a $200 million mix of venture funding and debt finance, San Diego-based Zogenix has filed an IPO intended to raise $90 million. The biotech company does have a product on the market: A needle-free device it's using to deliver a migraine therapy. And it has a pain therapy in late-stage development. Biotech IPOs haven't been warmly received by Wall Street this year. But the 2010 record is still better than 2009, when the public market was frozen to new entries. Zogenix dropped a planned offering back in 2008 as the market headed south. Story

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.